NervGen Pharma (NASDAQ:NGEN) Downgraded by Wall Street Zen to Strong Sell

Wall Street Zen lowered shares of NervGen Pharma (NASDAQ:NGEN) from a sell rating to a strong sell rating in a research report report published on Monday morning.

Separately, HC Wainwright initiated coverage on NervGen Pharma in a research note on Monday. They set a “buy” rating and a $18.00 target price for the company. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, NervGen Pharma currently has an average rating of “Hold” and an average price target of $18.00.

NervGen Pharma Price Performance

Shares of NGEN stock opened at $3.85 on Monday. NervGen Pharma has a 12-month low of $1.50 and a 12-month high of $6.30.

About NervGen Pharma

NervGen Pharma Corp. is a clinical-stage biotechnology company focused on developing therapies to promote nerve repair and restore neurological function following injury or disease. The company advances regenerative approaches intended to address damage in the central and peripheral nervous systems, pursuing programs that aim to translate preclinical repair concepts into human treatments.

The company’s lead investigational candidate is NVG-291, which is being evaluated in clinical studies for indications that include spinal cord injury, neuropathic conditions and neurodegenerative disease settings.